lung infection News
-
Beyond Air Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it ...
-
Beyond Air To Participate in Piper’s 34th Annual Healthcare Conference
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that ...
-
Beyond Air Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
-
Ash inhalation increases risk of lung infection
Inhaling volcanic ash could weaken the body’s natural defences against infection, a recent study concludes. A team of researchers collected samples of ash from the 2010 Eyjafjallajökull volcano eruption in Iceland and, in laboratory tests, found that they reduced the ability of immune cells in lungs to fight off bacterial infections. Volcanic air pollution has often been linked to ...
-
AlveoliX part of a new BRIDGE Discovery project
We are thrilled to be part of the new BRIDGE Discovery project granted by the SNSF Swiss National Science Foundation and Innosuisse to the Laboratory of Microbiology at the Université de Neuchâtel (LAMUN) in cooperation with the CHUV / Centre hospitalier universitaire vaudois, the SIB Swiss Institute of Bioinformatics, ...
By AlveoliX AG
-
SoeMac user testimonials - better breathing
We’re always pleased to receive a testimonial from any of our SoeMac users. Here are just a few shared recently with us by people who have found that SoeMac helps them to breathe more easily. Celia - Breathing Neil, thankyou so much for servicing my SoeMac. I received it back this morning and will clean it regularly as per the instructions. I am so grateful, SoeMac has really helped with ...
By SoeMac
-
AlveoliX and EpiEndo Receive Eurostar Grant
The Swiss National Science Foundation SNSF and the Swiss Innovation Agency Innosuisse have granted a BRIDGE Discovery project to the Laboratory of Microbiology at the University of Neuchâtel (LAMUN) in cooperation with the Centre Hospitalier Universitaire Vaudois (CHUV), the Swiss Institute of Bioinformatics (SIB), and two innovative Swiss startups AlveoliX AG and SiMPLInext SA. The aim of ...
By AlveoliX AG
-
Imspex’s patent portfolio grows
Imspex Diagnostics’ patent portfolio recently grew, with news that the European Patent Office has granted the patent “Method for measuring human exhaled air”. This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory ...
-
IAQ Marketing Specialist Reveals his Personal Fight with Mold
A fungal infection caused by Coccidioides immitis, also known as Valley Fever, took its toll on Paul Cochrane, President of Cochrane & Associates, LLC. In the October 2010 issue of Indoor Environment Connections a personal story of one of the industry’s own is detailed in an article entitled, “A Fungal Infection of the Lungs”. The article details the story of the ...
-
Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO
ALBUQUERQUE, N.M. (PRWEB) August 23, 2022 Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the drug ...
-
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
-
Nob Hill Therapeutics Announces Strategic Advisory Board to Accelerate Growth
Nob Hill Therapeutics has recruited global thought leaders to its Strategic Advisory Board. Albuquerque, NM - Nob Hill Therapeutics (NHT) is pleased to announce the members of its Strategic Advisory Board. Under the leadership of John Pritchard, PhD, the other members are: Caroline Baxter, MD, Charles Daley, MD and Noel Greenberger. The SAB brings together internationally renowned ...
-
Beyond Air Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
-
Microbion Corporation today announced that the company will present a poster highlighting the in vitro activity of pravibismane against M. avium and M. abscessus non-tuberculous mycobacteria (NTM) at the Colorado Mycobacteria Conference 2022: Focus on NTM
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”). The patent, entitled “Bismuth-thiol compositions and methods for treating wounds,” ...
-
Texas Residents with Immune System Deficiencies Cautioned to be on the Lookout for Indoor Mold
Last week, Governor Gregg Abbott added dozens of counties to his emergency declaration due to flooding and heavy rains across Texas. Countless homes and buildings have been damaged or destroyed by floodwaters and many others have suffered water damage due to leaking exteriors. All of this moisture has residents on the lookout for mold growth in their homes and businesses and those with a ...
-
Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
-
Synairgen provides update on ACTIV-2 Trial
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has halted all patient recruitment in its Phase 2/3 COVID-19 trial (Protocol ACTIV-2/A5401; ...
-
Synairgen presents at ATS 2022
Post hoc analyses conducted in patient populations at greater risk of progression to severe disease or death suggests that SNG001 may have an important clinical effect on top of standard of care Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the ...
-
Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include ...
-
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
Beyond Air, Inc. (NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you